AIM:Hepatic cavernous hemangioma (HCH) is the mostcommon benign tumor of the liver and its management isstill controversial.Recent success in situ radiofrequencyablation of hepatic malignancies has led us to consider usingthis technique in patients with HCH.This study was to assessthe efficacy,safety,and complications of percutaneousradiofrequency ablation (PRFA) under ultrasonographyguidance in patients with HCH.METHODS:Twelve patients (four men and eight women,age ranged 33-56 years,mean age was 41.7 years) with 15hepatic cavernous hemangiomas (2.5 cm to 9.5 cm) weretreated using the RF-2000 generator and 10-needle LeVeenelectrode percutaneously guided by B-ultrasound.Lesionslarger than 3 cm were treated by multiple overlappingablations that encompass the entire lesion as well as a rimof normal liver tissue (approximately 0.5 cm).RESULTS:All the patients who received PRFA therapy hadno severe pain,bleeding or bile leakage during and afterthe procedures.Nine to 34 months’ follow-up (mean,21months) by ultrasound and/or spiral CT scan demonstratedthat the ablated lesions in this group were shrunk remarkably,and the shrunken range was 38-79 % (mean,67 % per 21months).The contrast enhancement was disappeared withinthe tumor or at its periphery in all cases on spiral CT scansobtained 3 to 6 months after treatment.CONCLUSION:The results of this study suggest that PRFAtherapy is a mini-invasive,simple,safe,and effective methodfor the treatment of selected patients with HCH. AIM: Hepatic cavernous hemangioma (HCH) is the most common benign tumor of the liver and its management isstill controversial. Recent success in situ radiofrequency ablation of hepatic malignancies has led us to consider using technique in patients with HCH. This study was to assessthe efficacy, safety , and complications of percutaneous radiofrequency ablation (PRFA) under ultrasonographyguidance in patients with HCH.METHODS: Twelve patients (four men and eight women, age ranged 33-56 years, mean age was 41.7 years) with 15 hepatic cavernous hemangiomas (2.5 cm to 9.5 cm ) were treated using the RF-2000 generator and 10-needle LeVeenelectrode percutaneously guided by B-ultrasound. Lesions larger than 3 cm were treated by multiple overlapping ablations that encompass the entire lesion as well as a rim of normal liver tissue (approximately 0.5 cm) .RESULTS: All the patients who received PRFA therapy hadno severe pain, bleeding or bile leakage during and afterthe procedures. Nine to 34 months’ follow-up (m ean, 21months) by ultrasound and / or spiral CT scan demonstrated in the ablated lesions in this group were shrunk remarkably, and the shrunken range was 38-79% (mean, 67% per 21months). The contrast enhancement was disappeared with inthe tumor or at its periphery in all cases on spiral CT scansobtained 3 to 6 months after treatment. CONCLUSION: The results of this study suggest that PRFAtherapy is a mini-invasive, simple, safe, and effective method for the treatment of selected patients with HCH.